ClinicalTrials.gg
CompletedNCT06525649Updated Jul 16, 2025

A Double Blind, Randomized, Cross-over Study Examining the Suppression of the Photoparoxysmal EEG Response With NPT 2042

A Phase 1 interventional study of NPT 2042 in Photosensitive Epilepsy and Epilepsy, sponsored by NeuroPro Therapeutics, Inc.. Completed at 2 sites in United States. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2025-07-16.

Sponsored by NeuroPro Therapeutics, Inc. · Phase 1, Interventional, and Other

From the registry’s dates

  • Primary completion was Jun 2025, 1 year 4 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
5
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 793 studies in Epilepsy with a site in United States — 161 open to participants now, 194 under way, 17 of them phase 3. Epilepsy · United States.

Enrollment
525th of 588
5 · median 40
Started
2024
with 34 others
Phase 1
66 of 793
11 open now
Registered
715th of 793
by date

Among the 793 studies in Epilepsy with a site in United States, this one is the 525th largest by enrollment of the 588 interventional ones that give a count, is one of 35 that started in 2024, is one of 66 in phase 1, and was the 715th registered.

Epilepsy

1,848 studies on the registry are indexed under Epilepsy; 419 are open to participants now.

Browse Epilepsy studies →

Open to participants now

161 of the 793 studies in Epilepsy with a site in United States are open now. Recruiting first, the newest first:

156 more — sign in →

All 161 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 284 Epilepsy studies recruiting now, 114 (40%) set no upper age limit and 147 (52%) stop at 75 or younger; 139 take children under 18; 55 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 793 studies in Epilepsy with a site in United States, or all of them as a file.
02

Study summary

A double-blind, placebo-controlled, crossover trial to investigate the PPR of approximately 5 subjects with a known stable PPR on EEG, using 2 doses of NPT 2042 compared to placebo.

Read the detailed description

This study will compare the effect of 2 doses of NPT 2042 on the photoparoxysmal- electroencephalogram (EEG) response (PPR), compared to placebo. Subjects will be screened to ensure they have a stable PPR. Subjects will then return for 3 treatment visits, each lasting 1 day, with minimum 14-day washout period between visits. Subjects will be randomized to a treatment sequence in order to receive NPT 2042 (160 mg or 240 mg) or matching placebo on each treatment day. The PPR will be measured at predose (-0.5 hours) and 0.5, 1, 2, 3, 4, and 6 hours postdose. The PPR of the active treatments will be compared to the placebo response.

03

Conditions studied

  • Photosensitive Epilepsy
  • Epilepsy

Browse trials for

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Subject or legal authorized representative/guardian must be able to provide written signed prior to any study-specific procedures being conducted.
  2. Individuals aged 18-75 years at the time of consent.
  3. Subject has a diagnosis and history of a PPR with or without a diagnosis of epilepsy.
  4. Subjects receiving zero to three concomitant antiseizure medications (ASMs).

    • Benzodiazepines: the chronic use of a benzodiazepine for any indication will be allowed and will be counted as an ASM.
    • Vagus nerve stimulator (VNS)/responsive neurostimulation (RNS): VNS/RNS will not be counted toward the number of concomitant ASMs. Subjects with surgically implanted VNS/RNS will be allowed to enter the study if all the following conditions are met:

      • The device has been in place for 1 year or more prior to the screening visit.
      • The settings have remained constant for 3 months or more prior to the screening visit and remain constant throughout the study.
      • The battery is expected to last for the duration of the study.
  5. At least 3 of the EEGs performed during the screening visit must have an intermittent photic stimulation (IPS)-induced SPR of ≥3 points on a frequency assessment scale in the same eye condition, with documented confirmation by the Epilepsy Study Consortium, Inc. (ESCI).
  6. Subject is in otherwise good health (with the exception of epilepsy), as determined by the investigator and documented in the medical history.
  7. Subject has a (BMI) between 18 and 40 kg/m2.
  8. Subject agrees to refrain from strenuous exercise which is not within the subject's normal daily routine the day before screening, as determined by the investigator.
  9. Female subjects of and all men: agree to use of highly effective methods of during the study and for 28 days after last dose of study drug.
  10. Subject is able to communicate with the investigator and to understand and comply with all study requirements.

Exclusion criteria

Exclusion Criteria:

  1. Subject has a history of non-epileptic seizures (e.g., metabolic, structural, or pseudoseizures).
  2. Females who are pregnant or lactating.
  3. Subject has a laboratory abnormality that, in the opinion of the investigator, will exclude the subject from the study.
  4. Subject has an active central nervous system (CNS) infection, demyelinating disease, degenerative neurological disease, or any CNS disease deemed to be progressive during the course of the study that may confound the interpretation of the study results.
  5. Subject has any clinically significant psychiatric illness, psychological, or behavioral problems which, in the opinion of the investigator, would interfere with the subject's ability to participate in the study.
  6. Subject has clinically significant active liver disease (i.e., liver function tests greater than 3 times the (AST), or alanine aminotransferase (ALT), porphyria, or has a family history of severe hepatic dysfunction.
  7. Subject has a history of alcoholism, drug abuse, or drug addiction within the past 12 months.
  8. Subjects who have participated in any other trials involving an product or device within 30 days or five half-lives (whichever is longer) of Screening.
  9. Subject is currently using of any prohibited medication, food or supplement
  10. Inability of the investigator to reliably distinguish between spontaneous and provoked spike-wave burst discharges.
  11. Subject uses a benzodiazepine as rescue medication within 24 hours of screening. If, in the judgment of the investigator, the subject meets all of the inclusion and none of the other exclusion criteria, rescreening may be done after appropriate . If no other rescue medications have been used within the past month, the subject may be eligible for rescreening.
  12. Subject has more than one use of rescue medications in the past 30 days.
  13. Subject has a history of suicidal thoughts or behaviors in the past 6 months or more than one lifetime suicide attempt.
  14. Subject is unable to complete ingestion of 12 placebo SGCs with a minimum of 8 ounces of water at screening.
  15. Subject has a clinically significant medical condition that would interfere with the subject's ability to participate in the study (e.g. active cancer, cardiac disease, renal insufficiency, or active infectious processes).
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
5 participants (actual)

Study arms

  • Placebo comparator
    Placebo

    Matching placebo for active comparator.

    Drug: NPT 2042

  • Active comparator
    NPT 2042 160mg

    NPT 2042

    Drug: NPT 2042

  • Active comparator
    NPT 2042 240mg

    NPT 2042

    Drug: NPT 2042

Interventions

  • NPT 2042 is a new drug being developed as an anti-seizure treatment.

06

What researchers measure

Primary outcomes

  1. Evaluate the change in the adjudicated SPR (standard photosensitivity range)

    Evaluate the change in the adjudicated SPR (standard photosensitivity range) in subjects receiving each different dose strengths of NPT 2042 compared to placebo in the most sensitive eye condition. The most sensitive eye condition will be determined at the screening visit.

    Time frame: Through study completion, an average of 4 months

Secondary outcomes

  1. Change in adjudicated SPR

    Evaluate the change in adjudicated SPR in subjects receiving each dose strength of NPT 2042 compared to placebo in all eye conditions.

    Time frame: Through study completion, an average of 4 months

  2. Explore the time of PPR effect to the NPT 2042 and metabolite plasma concentration-time profiles in the most sensitive eye condition.

    Explore the time of PPR effect to the NPT 2042 and metabolite plasma concentration-time profiles in the most sensitive eye condition.

    Time frame: Through study completion, an average of 4 months

  3. Explore the onset of PPR effect to the NPT 2042 and metabolite plasma concentration-time profiles in all eye conditions.

    Explore the onset of PPR effect to the NPT 2042 and metabolite plasma concentration-time profiles in all eye conditions.

    Time frame: Through study completion, an average of 4 months

  4. Explore the duration of PPR effect to the NPT 2042 and metabolite plasma concentration-time profiles in all eye conditions.

    Explore the duration of PPR effect to the NPT 2042 and metabolite plasma concentration-time profiles in all eye conditions.

    Time frame: Through study completion, an average of 4 months

07

Study locations

2 sites
  • Clinical Trials, Inc. (CTI)
    Little Rock, Arkansas 77205, United States
  • Idaho Comprehensive Epilepsy Center
    Boise, Idaho 83702, United States
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2024 to primary completion in Jun 2025, 10 months.

Of 34 industry-sponsored phase 1 interventional studies under Epilepsy, half reached primary completion within 4 months of starting (the median), counting those still running; a quarter within 1 and three quarters within 10. This study's 10 months is above that.

Counting every sponsor, half of 55 studies reached it within 8 months; a quarter within 3 and three quarters within 22.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 15, 2024
First posted
Jul 29, 2024
StartActual
Aug 21, 2024
Primary completionActual
Jun 26, 2025
CompletionActual
Jun 26, 2025
Last update
Jul 16, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 16, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06525649
Lead sponsor
NeuroPro Therapeutics, Inc.
Collaborators
The Epilepsy Study Consortium
Responsible party
Sponsor
First posted
Jul 29, 2024
Start date
Aug 21, 2024
Primary completion
Jun 26, 2025
Completion
Jun 26, 2025
Last update
Jul 16, 2025

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: NPT 2042

Start the discussion